Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil

Kallas, Esper Georges; Precioso, Alexander Roberto; Palacios, Ricardo; Thomé, Beatriz; Braga, Patrícia Emília; Vanni, Tazio; Campos, Lúcia M A; Ferrari, Lilian; Mondini, Gabriela; Salomão, Maria da Graça; Silva, Anderson da; Espinola, Heloisa Maxímo; Santos, Joane do Prado; Santos, Cecilia L S; Timenetsky, Maria do Carmo S T; Miraglia, João Luiz; Gallina, Neuza Maria Frazatti; Weiskopf, Daniela; Sette , Alessandro; Goulart, Raphaella; Salles, Rafael Tavares; Maestri, Alvino; Sallum, Adriana Maluf Elias; Farhat, Sylvia Costa Lima; Sakita, Neusa Keico; Ferreira, Juliana C O A; Silveira, Cassia G T; Costa, Priscilla R; Raw, Isaias; Whitehead, Stephen S; Durbin, Anna P.; Kalil, Jorge

Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial

Document type

Article

Source

Kallas EG, Precioso AR, Palacios R, Thomé B, Braga PE, Vanni T, et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect. Dis.. 2020 Mar;20(7):839-850. doi:10.1016/S1473-3099(20)30023-2.